NASHUA, N.H., May 15, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD) a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the three months ended March 31, 2024. First Quarter 2024 Highlights (Year over Year Performance): Total ARR was $9.0 million, up 10% Total revenues were $5.0 million, up 14% Gross Profit Margin % was 83%, up from 82% GAAP Net Loss from continuing operations ($1.2) million, improvement from ($3.1) million Operating cash flow was ($1.2) million, improvement from ($1.5) million "Over the past year, we have demonstrated strong execution of our three-phased transformation plan that has positioned iCAD for growth and created a platform to drive additional shareholder value," said Dana Brown, President and CEO of iCAD, Inc. "Phases 1 and 2 of our transformation plan focused on realigning the company's base and strengthening its foundation. These efforts stabilized cash burn, fortified leadership, increased cash on hand and repositioned iCAD for growth in 2024 and beyond. Phase 3, "Investing in Growth," commenced this quarter with a focus on expanding into key accounts and new markets. We are seeing the early signs of success from our key growth initiatives that included targeted lead generation programs, a revamped commercial model, strategic additions to the sales team, and new enhancements to our ProFound Breast Health Suite including release of ProFound Cloud." Three Months Ended March 31, 2024 Financial Results Total revenue for the first quarter of 2024 was $5.0 million, an increase of $0.6 million, or 14%, as compared to the first quarter of 2023. (in 000's)   Three months ended March 31,       2024     2023     $ Change     % Change   Product revenue   $ 3,102     $ 2,460     $ 642       26.1 % Service and supplies revenue     1,852       1,874       (22 )     -1.2 % Total revenue   $ 4,954     $ 4,334     $ 620       14.3 % Gross Profit: Gross profit for the first quarter of 2024 was $4.1 million, or 83% of revenue, as compared to $3.5 million, or 82% of revenue, in the first quarter of 2023. Operating Expenses: Total operating expenses for the first quarter of 2024 were $5.6 million, an 18% decrease from $6.8 million in the first quarter of 2023. GAAP Net Loss from continuing operations: Net loss from continuing operations for the first quarter of 2024 was ($1.2) million, or ($0.05) per diluted share, as compared to a net loss of ($3.1) million, or ($0.12) per diluted share, for the first quarter of 2023. Non-GAAP Adjusted Net Loss from continuing operations: Non-GAAP Adjusted Net Loss from continuing operations, a non-GAAP financial measure as defined below, for the first quarter of 2024 was ($1.2) million, or ($0.05) per diluted share, as compared to a Non-GAAP Adjusted Net Loss of ($2.9) million, or ($0.12) per diluted share, for the first quarter of 2023. Please refer to the section entitled "Reconciliation of Non-GAAP Financial Measures to Comparable GAAP Measures" and the accompanying financial table included at the end of this release for a reconciliation of GAAP Net Loss to Non-GAAP Adjusted Net Loss results for the three-month periods ended March 31, 2024 and 2023, respectively. Non-GAAP Adjusted EBITDA: Non-GAAP Adjusted EBITDA, a non-GAAP financial measure as defined below, for the first quarter of 2024 was a loss of ($1.1) million compared to a loss of $(2.4) million in the first quarter of 2023. Please refer to the section entitled "Reconciliation of Non-GAAP Financial Measures to Comparable GAAP Measures" and the accompanying financial table included at the end of this release for a reconciliation of GAAP Net Loss to Non-GAAP Adjusted EBITDA results for the three-month periods ended March 31, 2024 and 2023, respectively. Cash and cash equivalents:  Cash and cash equivalents were $20.3 million as of March 31, 2024.  iCAD believes it has sufficient cash resources to fund its planned operations with no need to raise additional funding. Conference Call: A conference call will be held today, Wednesday, May 15, 2024 at 8:30 AM ET. Domestic:   877-545-0523 International:    973-528-0016 Access Code:   730845 Webcast:   https://www.webcaster4.com/Webcast/Page/2879/50453       Use of Non-GAAP Financial MeasuresIn its quarterly news releases, conference calls, slide presentations or webcasts, the Company may use or discuss non-GAAP financial measures as defined by SEC Regulation G. The GAAP financial measures most directly comparable to each non-GAAP financial measure used or discussed, and a reconciliation of the differences between each non-GAAP financial measure and the comparable GAAP financial measure, are included in this press release after the condensed consolidated financial statements. When analyzing the Company's operating performance, investors should not consider these non-GAAP measures as a substitute for the comparable financial measures prepared in accordance with GAAP. The Company's quarterly news releases containing such non-GAAP reconciliations can be found on the Investors section of the Company's website at www.icadmed.com About iCAD, Inc.iCAD, Inc. (NASDAQ:ICAD) is a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes. Headquartered in Nashua, N.H., iCAD's industry-leading ProFound Breast Health Suite provides AI-powered mammography analysis for breast cancer detection, density assessment and risk evaluation. Used by thousands of providers serving millions of patients, ProFound is available in over 50 countries. In the last five years alone, iCAD estimates reading more than 40 million mammograms worldwide, with nearly 30% being tomosynthesis. For more information, including the latest in regulatory clearances, please visit www.icadmed.com. Forward-Looking StatementsCertain statements contained in this News Release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the expansion of access to the Company's products, improvement of performance, acceleration of adoption, expected benefits of ProFound AI®, the benefits of the Company's products, and future prospects for the Company's technology platforms and products. Such forward-looking statements involve a number of known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited, to the Company's ability to achieve business and strategic objectives, the willingness of patients to undergo mammography screening in light of risks of potential exposure to Covid-19, whether mammography screening will be treated as an essential procedure, whether ProFound AI will improve reading efficiency, improve specificity and sensitivity, reduce false positives and otherwise prove to be more beneficial for patients and clinicians, the impact of supply and manufacturing constraints or difficulties on our ability to fulfill our orders, uncertainty of future sales levels, to defend itself in litigation matters, protection of patents and other proprietary rights, product market acceptance, possible technological obsolescence of products, increased competition, government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company's filings with the Securities and Exchange Commission. The words "believe," "demonstrate," "intend," "expect," "estimate," "will," "continue," "anticipate," "likely," "seek," and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at http://www.icadmed.com and on the SEC's website at http://www.sec.gov. CONTACTS Media inquiries: Inquiries: iCAD, INC. AND SUBSIDIARIES Condensed Consolidated Balance Sheets (In thousands, except for share data)(Unaudited)     Mar 31,     Dec 31,       2024     2023   Assets                 Current assets:                 Cash and cash equivalents   $ 20,284     $ 21,670   Trade accounts receivable, net of allowance for credit losses of $298 and $277 as of March 31, 2024 and December 31, 2023, respectively     6,515       6,392   Inventory, net     750       917   Prepaid expenses and other current assets     1,495       699   Total current assets   $ 29,044     $ 29,678   Property and equipment, net of accumulated depreciation of $1,136 and $1,045 as of March 31, 2024 and December 31, 2023, respectively     1,938       1,823   Operating lease assets     522       461   Other assets     299       849   Intangible assets, net of accumulated amortization of $8,500 and $8,488 as of March 31, 2024 and December 31, 2023, respectively     136       148   Goodwill     8,362       8,362   Deferred tax assets     94       97   Total assets   $ 40,395     $ 41,418   Liabilities and Stockholders' Equity                 Current liabilities:                 Accounts payable   $ 635     $ 712   Accrued and other expenses     1,755       2,448   Lease payable—current portion     216